The robustness of key signaling molecules (e.g., EZH2, FOXA1, and ESR1) was confirmed using an independent dataset, providing novel insights into the regulatory mechanisms of the TIME in ER+ breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.